Promising combo aims to boost Cancer-Free survival in head and neck cancer

NCT ID NCT07524452

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether adding a targeted drug (becotatug vedotin) to standard immunotherapy (a PD-1 inhibitor) before and after surgery can help people with a certain type of head and neck cancer live longer without the cancer coming back. About 430 adults with EGFR-positive, CPS≥1 resectable locally advanced head and neck squamous cell carcinoma will be randomly assigned to receive the combination or immunotherapy alone. The main goal is to see if the combo improves event-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
becotatug vedotin (a targeted drug) plus pucotenlimab (an immunotherapy)
What this could lead to
If successful, this combination could become a new standard treatment before and after surgery for certain head and neck cancers, potentially improving the chance of staying cancer-free.
What could go wrong
This is still an experimental approach; the added drug may cause more side effects and it's unknown if it will truly improve outcomes over the immunotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Fifth Affiliated Hospital,Sun Yat-sen University

    RECRUITING

    Zhuhai, Guangdong, 519099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.